Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
Blood. 2011 Sep 8;118(10):2896-905. doi: 10.1182/blood-2011-01-330589. Epub 2011 Jun 28.
miRNAs have emerged as master regulators of cancer-related events. miRNA dysregulation also occurs in Kaposi sarcoma (KS). Exploring the roles of KS-associated miRNAs should help to identify novel angiogenesis and lymphangiogenesis pathways. In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated. Both latent nuclear antigen (LANA) and Kaposin B repress the expression of the miR-221/miR-222 cluster, which results in an increase of endothelial cell (EC) migration. In contrast, miR-31 stimulates EC migration, so depletion of miR-31 in KSHV-transformed ECs reduces cell motility. Analysis of the putative miRNA targets among KSHV-affected genes showed that ETS2 and ETS1 are the downstream targets of miR-221 and miR-222, respectively. FAT4 is one of the direct targets of miR-31. Overexpression of ETS1 or ETS2 alone is sufficient to induce EC migration, whereas a reduction in FAT4 enhances EC motility. Our results show that KSHV regulates multiple miRNA-mRNA networks to enhance EC motility, which eventually contributes to KS progression by promoting the spread of malignant KS progenitor cells. Targeting KSHV-regulated miRNAs or genes might allow the development of novel therapeutic strategies that induce angiogenesis or allow the treatment of pathogenic (lymph)angiogenesis.
miRNAs 已成为癌症相关事件的主要调控因子。miRNA 失调也发生在卡波西肉瘤(KS)中。探索与 KS 相关的 miRNAs 的作用应该有助于识别新的血管生成和淋巴管生成途径。在本研究中,我们表明卡波西肉瘤相关疱疹病毒(KSHV),KS 的病因,在淋巴内皮细胞(LEC)中诱导全局 miRNA 变化。具体而言,miR-221/miR-222 簇下调,而 miR-31 上调。潜伏核抗原(LANA)和 Kaposin B 均抑制 miR-221/miR-222 簇的表达,导致内皮细胞(EC)迁移增加。相反,miR-31 刺激 EC 迁移,因此在 KSHV 转化的 EC 中耗尽 miR-31 可降低细胞迁移率。对 KSHV 影响的基因中的假定 miRNA 靶标进行分析表明,ETS2 和 ETS1 分别是 miR-221 和 miR-222 的下游靶标。FAT4 是 miR-31 的直接靶标之一。ETS1 或 ETS2 的单独过表达足以诱导 EC 迁移,而 FAT4 的减少增强了 EC 的迁移能力。我们的研究结果表明,KSHV 调节多个 miRNA-mRNA 网络以增强 EC 迁移,这最终通过促进恶性 KS 祖细胞的扩散来促进 KS 的进展。靶向 KSHV 调节的 miRNAs 或基因可能允许开发新的治疗策略,诱导血管生成或允许治疗致病性(淋巴)血管生成。